Tranexamic acid reduces blood loss and transfusions in TKA and THA .
Este estudio ha sido identificado como potencialmente de alto impacto.
La métrica de alto impacto de OE, impulsada por la IA, estima la influencia que probablemente tendrá un artículo integrando señales tanto de la revista en la que se publica como del contenido científico del propio artículo.
Desarrollado mediante el procesamiento del lenguaje natural más avanzado, el modelo de Alto Impacto de OE predice con mayor precisión el futuro rendimiento de las citas de un estudio que el factor de impacto de la revista por sí solo.
Esto permite reconocer antes las investigaciones clínicamente significativas y ayuda a los lectores a centrarse en los artículos con más probabilidades de configurar la práctica futura.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2013;1(10):12 BMC Res Notes. 2013 May 7;6:184. doi: 10.1186/1756-0500-6-18433 RCTs (1,957 patients), reporting the use of tranexamic acid (TXA) in total hip arthroplasty or total knee arthroplasty compared to a control, were selected in this meta-analysis. The findings calculating the efficacy of tranexamic acid in reducing in blood loss, number of patients requiring allogeneic blood transfusions, and risk of deep vein thrombosis (DVT) indicated better outcomes in favour of tranexamic acid for both THA and TKA.
Were the search methods used to find evidence (original research) on the primary question or questions stated?
Was the search for evidence reasonably comprehensive?
Were the criteria used for deciding which studies to include in the overview reported?
Was the bias in the selection of studies avoided?
Were the criteria used for assessing the validity of the included studies reported?
Was the validity of all of the studies referred to in the text assessed with use of appropriate criteria (either in selecting the studies for inclusion or in analyzing the studies that were cited)?
Were the methods used to combine the findings of the relevant studies (to reach a conclusion) reported?
Were the findings of the relevant studies combined appropriately relative to the primary question that the overview addresses?
Were the conclusions made by the author or authors supported by the data and or analysis reported in the overview?
How would you rate the scientific quality of this evidence?
Sí = 1
Incierto = 0,5
No relevante = 0
No = 0
La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.
4/4
Introduction
3/4
Accessing Data
4/4
Analysing Data
3/4
Results
3/4
Discussion
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.
¿Por qué se necesitaba ahora este estudio?
With the increasing number of TKAs and THAs being performed, the issue of blood loss and subsequent high risk of blood transfusions is an increasingly important issue. Substantial blood loss can lead to postoperative anemia, infections, cardiopulmonary events, and increased costs. To counteract these effects, tranexamic acid (TXA), applied topically or intravenously, has been used in many surgeries, but it's risk of causing deep vein thrombosis (DVT) is of some concern. Therefore, this meta-analysis was conducted to investigate the effects of TXA in reducing blood loss and allogenic transfusion requirements without causing DVT.
¿Cuál era la pregunta principal de la investigación?
Does tranexamic acid (TXA) reduce total blood loss and number of patients requiring allogenic blood transfusions, compared to a control, in patients undergoing THA and TKA?
- In 14 studies with TKA, the combined total blood loss favoured TXA patients, WMD = -1.149 (p < 0.001; 95% CI −1.298 to -1.000). The heterogeneity of these results was high (p = 0.000, I2 = 85.710). After sensitivity analysis considering heterogeneity, TXA showed superiority over control; WMD = −1.706 (p < 0.001, 95% CI −1.949 to-1.463).
- In 12 studies with THA, the combined total blood loss also favoured TXA, WMD = −0.504 (p<0.001; 95% CI, -0.672, -0.336). A moderate level of heterogeneity was found (p = 0.006, I2 = 58.000).
- In 16 studies with TKA, the combined OR of number of patients receiving allogeneic blood transfusions was 0.145 (p < 0.001; 95% CI, 0.094, 0.223) in favour of TXA group. The results were homogenous (p =0.801, I2 = 0.000).
- In 10 studies with THA, the combined OR for number of patients receiving allogeneic blood transfusions was 0.327 (p < 0.001; 95% CI, 0.208, 0.515) in favour of TXA. The heterogeneity of the results was moderate (p = 0.135, I2 = 34.089).
- In 7 studies with TKA, the combined OR of number of patients who developed DVT was 1.030 (p = 0.946; 95% CI, 0.439, 2.420), showing no increase in DVT incidences with TXA use. The results were homogenous (p =0.615, I2 = 0.000).
- In 5 studies with THA, the combined OR for the number of patients who developed a DVT was 1.070 (p = 0.895; 95% CI, 0.393, 2.911), showing no increase in DVT incidences with TXA use. The results were homogenous (p =0.677, I2 = 0.000).
- In TXA groups, 30 DVT, 3 pulmonary embolisms (PE), 1 myocardial infarction, 3 wound infections, 9 wound hematomas, and 1 chest infection occurred. In control groups 20 DVT, 4 PE, 5 wound infections, and 6 wound hematomas occurred.
¿Qué es lo que más debo recordar?
The use of TXA significantly reduced the total blood loss and number of patients requiring blood allogeneic blood transfusions after THA and TKA, without an increased risk of thromboembolic complications.
¿Cómo afectará esto al cuidado de mis pacientes?
The study supports the use of TXA in major surgeries such as TKA and THA. However, more meta-analyses with poolable data regarding thromboembolic complications are needed to confirm these findings.
DESCARGO DE RESPONSABILIDAD
El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.
0 de 4 artículos mensuales GRATIS desbloqueados
